Financials data is unavailable for this security.
View more
Year on year Cartesian Therapeutics Inc 's revenues fell -76.53% from 110.78m to 26.00m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 35.38m to a loss of 219.71m.
| Gross margin | -- |
|---|---|
| Net profit margin | -510.72% |
| Operating margin | -111.60% |
| Return on assets | -87.23% |
|---|---|
| Return on equity | -801.65% |
| Return on investment | -94.16% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Cartesian Therapeutics Inc fell by 29.75m. However, Cash Flow from Investing totalled 34.61m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 51.16m for operations while cash used for financing totalled 13.15m.
| Cash flow per share | -16.54 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0315 |
|---|---|
| Tangible book value per share | -8.29 |
More ▼
Balance sheet in USDView more
| Current ratio | 10.70 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
